Open Access

Estimating the survival advantage based on telomere length and serum biomarkers of aging

Journal of Translational Medicine201715:166

https://doi.org/10.1186/s12967-017-1267-8

Received: 16 May 2017

Accepted: 19 July 2017

Published: 1 August 2017

Abstract

Background

This study aimed to establish a model that estimates the survival advantage at the molecular level based on telomere length and serum biomarkers of aging, to explore clinical significance.

Methods

The study consisted of 100 healthy subjects and 40 type 2 diabetes mellitus patients, 20–90 years of age. Saliva telomere relative length (LnTL) was measured by the quantitative real-time polymerase chain reaction and the serum biochemical parameters, including albumin (ALB), total proteins, total cholesterol, triglycerides, and some enzyme parameters were detected by a biochemical analyzer. The Z values were transformed from mean values and standard deviations to estimate the survival advantage. A normal reference range (95% confidence interval) was set to the comprehensive advantage of the Z values (Zs) to evaluate the comprehensive survival advantage.

Results

The Z values of serum ALB and saliva LnTL could be used to estimate the survival advantage, and effectively distinguish between the aging and nonaging individuals. The Zs was greater than 1.64 in the normal reference range, and type 2 diabetes mellitus patients had lower survival advantages compared to those of the control group (p < 0.05).

Conclusions

Our two-dimensional model system using ALB and LnTL was valid and may have potential applications for evaluating the aging status at the molecular level, and for the observation of disease characteristics.

Keywords

Aging Albumin Telomere length Survival advantage

Background

The survival advantage is the indicator that reflects the ability to resist environment and oxidative stress and other adverse conditions that are essential for health assessments to predict the survival advantage [1, 2]. The survival advantage model we studied was defined as the stronger survival potential ability of an individual among her/his peers, showing a longer life expectancy. At present, only using aging markers to evaluate healthy body status is not comprehensive [3], and therefore the survival advantage of this type of study is decreased. We evaluated the survival advantage based on the molecular markers of aging to establish a survival advantage model.

The breakdown of tissues and organs by diseases or aging was first revealed on a molecular level, and involves the long-term accumulation of DNA damage leading to cellular aging and death [4]. This could affect survival ability; therefore, health assessments may be related to early molecular changes that could be used to quantitate the health problems of aging. Because the aging process is dynamic, aging biomarkers are often incorporated into a model of survival advantage [5, 6].

At present, most of the biomarkers of aging include changes in DNA, RNA, proteins, and body fluids, which can reflect the degree of aging [7, 8]. Telomere length has been recognized as an excellent marker of aging [9]. The telomere is a complex composed of specific proteins and telomeric DNA, and is located at the two terminal ends of eukaryotic chromosomes. Telomeres play an important role in maintaining chromosome stability [10, 11]. However, hereditary traits, various oxidative stresses, and the environment reduce telomerase activity in the cortex and gray matter, myocardial cells, germ cells, and almost all somatic cells. The telomere DNA gradually shortens, eventually leading to cell senescence and death. The measurement of telomere length can be used to evaluate the aging status of the organism at the molecular level, and could further reflect genetic changes [12, 13].

In individuals older than 75 years, telomere length increased with age when compared to individuals less than 75 years old [14, 15]. Regarding these findings, we hypothesized that in the same age range, individuals with longer telomeres versus shorter telomeres did not die at the same time, and when compared with the subjects in the long telomere length group, those individuals in the short telomere length group had a higher probability of mortality. Therefore, longer telomeres showed a significant survival advantage in elderly people. However, in addition to telomere length, we screened for additional serum markers of aging to establish a more robust model that included multiple parameters.

Changes in serum proteins, total cholesterol, triglycerides, enzymes, and other biochemical components are observed with aging [1618]. The physiological functions of individuals at increasing ages can be measured as abnormal cellular responses to environmental stimuli or stress. Senescent cells show a decline in their physiological function as reflected in abnormal metabolic products that can be measured in the blood [12, 19]. Even in the absence of a disease, older individuals still exhibit great differences in the concentrations and the basic structures of proteins compared with that of younger individuals [7, 20].

With aging, serum lipid breakdown is reduced, cholic acid levels are decreased, and increased total cholesterol content in the liver is observed [21]. The physiological changes caused by aging also cause a functional decline of organs [22]. In addition, the age-affected enzymes in the serum could cause abnormal metabolism, and changes in biochemical components in the blood could indirectly reflect the aging status [23]. These biochemical indicators could be used to quickly and conveniently detect changes with aging, and may provide for more accurate and objective information.

We screened representative markers of aging, and with age, the probability of death was uniform. When compared with other aging markers, telomere length reflected the individual survival advantage, and specific biomarkers of aging were more likely to reflect the overall population aging condition [1, 9]. However, because the parameters were different, their combined use estimated a survival advantage on the molecular level. The main purpose of this study was to establish a survival advantage model, to determine if telomere length together with serum markers of aging at the molecular level could be used to evaluate the clinical significance of aging.

Type 2 diabetes mellitus is a degenerative disease associated with aging [24]. It mostly occurs in the elderly population, and samples are easy to obtain. Notably, diabetes mellitus is easy to diagnose and the diagnostic parameters are objective and accurate. In this study, type 2 diabetes was used to verify the two-dimensional survival advantage model that we have established.

Methods

Subjects

The study was approved by the Institutional Ethics Committee of Dalian Medical University and all subjects agreed to participant in the experiment. From July 2016 to August 2016, 100 healthy volunteers and 40 volunteers with type 2 diabetes mellitus patients were enrolled at the Second Affiliated Hospital of Dalian Medical University (Dalian, China). The inclusion criteria of healthy subjects were: no medication or recent diseases, and females not in their menstrual cycle. Type 2 diabetes mellitus patients were included according to these diagnostic criteria: (1) glycated hemoglobin A1c ≥ 6.5%; (2) fasting plasma glucose ≥ 7.0 mmol/L; or (3) blood glucose at 2 h in the oral glucose tolerance test ≥11.1 mmol/L. The exclusion criteria were: diabetes mellitus patients with complications of heart disease or liver cancer; individuals with a chronic disease that would affect the collection of saliva and telomere length measurement, such as smokers, drinkers, subjects suffering from an oral disease, pregnant women, or those with mental illnesses. This study conformed to the tenets of the Declaration of Helsinki regarding the use of human subjects in research.

Saliva and serum collection

The saliva of all subjects were collected using specialized salivary collection tubes without any additives (Salivette®; Sarstedt, Nümbrecht, Germany) in the morning between 07:00 am and 08:00 am, in a quiet and calm environment. Before the saliva collection, the subjects were asked to avoid drinking water, brushing their teeth, smoking, or chewing food or gum for 30 min. They were advised to then chew on a cotton swab for approximately 45 s; the swab was then placed in the saliva collection tube. The entire collection tube with the swab was centrifuged at 1000×g for 2 min, resulting in approximately 1 mL of collected supernatant. After fasting for at least 8 h, a peripheral blood sample was collected, then the sample was centrifuged at 1500×g for 10 min, and the supernatant was frozen at −20 °C until further analysis. Saliva and serum were collected from the same subjects at 24 h.

DNA extraction and telomere length assay

Salivary DNA samples were extracted using a DNA extraction kit (Omega Biotek, Norcross, GA, USA). Two hundred microliters of supernatant from the saliva was used for the extraction of genomic DNA. A spectrophotometer (Thermo Fisher, Waltham, MA, USA) was used to measure the concentration and purity of the DNA that was then stored in a freezer at −20 °C.

Telomere relative length was measured using the fluorescence quantitative polymerase chain reaction (PCR) method of Cawthon [25] to calculate the ratio of the telomere gene to a single copy gene (T/S), and the T/S was proportional to the relative length of the telomere, therefore, T/S was used to express the relative length of the telomere obtained from the saliva.

The upstream primer sequence of the telomere gene was as follows:

5ʹ-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3ʹ.

The downstream primer sequence of telomere gene was as follows:

5ʹ-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT-3ʹ.

The telomere gene product fragment was 76 base pairs (bp). The upstream primer sequence of the single gene (36B4) was as follows: 5ʹ-CAGCAAGTGGGAAGGTGTAATCC-3ʹ; and the downstream primer sequence of the single gene (36B4) was as follows:

5ʹ-CCCATTCTATCATCAACGGGTACAA-3ʹ.

The 36B4 gene product fragment was 63 bp.

All quantitative (q) PCR were performed on the Thermal Cycler Dice Real Time System Single and Lite (TaKaRa, Kyoto, Japan). We used Cawthon’s qPCR method with modifications that input 5 ng DNA [25], and the experimental conditions were 40 cycles, a pre-denaturation temperature of 95 °C, for 30 s; a denaturation temperature of 95 °C, for 15 s, and an annealing temperature of 60 °C for 1 min. Each sample contained three parallel samples, and the average value was taken to calculate T/S. The formula was as follows:
$$ \Delta {\text{Ct}} = {\text{Ct}}_{\text{TEL}} - {\text{Ct}}_{36B4} ,\;{\text{relative}}\;{\text{T/S}}\;({\text{TL}}) = 2^{{ - [({\text{CtTel}} - {\text{Ct}}36B4) - ({\text{CtTel}} - {\text{CtControl}})]}} ,\;{\text{then}}\;{\text{TL}} = 2^{{ - \Delta \Delta {\text{Ct}}}} . $$

Biochemical parameter assays

All serum sample assays were performed on the automatic biochemical analyzer (Hitachi 7600-110; Hitachi, Tokyo, Japan). The parameters included albumin (ALB), total protein (TP), total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), and lactate dehydrogenase (LDH). The indoor environment was controlled, and all the parameters were detected on the same day with the entire determination completed within 2 h.

Statistical analysis and model establishment

The relative length of the salivary telomeres gave a skewed distribution; therefore, the data were transferred into a natural logarithm and analyzed for the saliva telomere relative length (LnTL). The healthy subjects were divided into groups in a 10-year age range, and the serum biochemical parameters were expressed as medians. The relationship between the biomarkers and age was analyzed by curve regression and scatter plot analyses. Nonparametric tests were used to analyze the variations of different groups. The mean value and standard deviation of each index in all healthy subjects were calculated, and the Z value was calculated as:

Albumin (ALB), total proteins (TP), and LnTL: \( {\text{Z}} = ({\bar{\text{X}}} - {\text{X}})/{\text{S}} \) [26, 27].

TC, TG, AST, ALT, ALP, GGT, and LDH: \( {\text{Z}} = ({\text{X}} - {\bar{\text{X}}})/{\text{S}} . \)
$$ {\text{Z}}_{\text{s}} = [{\text{Z}}\;({\text{LnTL}}) + {\text{Z}}({\text{ALB}})]/2 $$

The Z value was used to establish the survival advantage model, and the χ 2 test was used to analyze the difference between the groups. All statistical analyses used SPSS software (SPSS, Chicago, IL, USA), and a value of p < 0.05 (bilateral) was considered as statistically significant.

Results

The saliva LnTL and serum biochemical parameters including ALB, TP, TC, TG, ALT, AST, ALP, GGT, and LDH were analyzed among the different age groups. The results are listed in Table 1. The ALB concentration decreased with age and showed a good correlation with age, (R2 = 0.968, p < 0.001) (Fig. 1). The LnTL gradually decreased with age, but in the group >65 years of age, there was a reverse rise; similarly, the TC and TG increased gradually before 75 years of age, but decreased in the >75 years of age group, as is shown in Fig. 2.
Table 1

Distributions of LnTLs and biochemical parameters in the different age groups

Group (years)

LnTL

ALB (g/L)

TP (g/L)

TC (mmol/L)

TG (mmol/L)

ALT (U/L)

AST (U/L)

ALP (U/L)

GGT (U/L)

LDH (U/L)

20–29

0.40

47.85

73.75

4.10

0.84

6.00

14.00

62.00

14.00

140.00

30–39

0.29

47.30

74.45

4.48

1.04

10.50

18.00

70.00

18.50

143.50

40–49

−0.12

47.00

74.50

5.12

1.27

10.00

16.00

59.00

21.00

156.00

50–59

−0.47

45.85

75.10

5.40

1.58

12.00

21.00

70.00

28.50

157.50

60–69

−0.67

44.65

70.50

5.79

1.67

7.50

17.00

78.50

20.00

178.00

70–79

−0.56

44.64

74.40

6.29

1.75

9.00

17.00

81.50

23.00

172.50

80–89

−0.22

43.50

71.50

5.56

1.22

8.00

19.00

74.00

19.00

177.00

N

98

100

100

100

100

100

100

100

100

100

p

0.677

<0.001

0.446

<0.001

0.009

0.102

0.002

0.051

0.014

<0.001

All parameters are represented by as median

LnTL the natural logarithm of telomere length, ALB albumin, TP total proteins, TG triglycerides, TC total cholesterol, ALT alanine amino transferase, AST aspartate amino transferase, ALP alkaline phosphatase, GGT gamma glutamyl transferase, LDH lactate dehydrogenase

Fig. 1

Linear relationship between ALB concentration and age. p < 0.001, R2 = 0.968. ALB albumin

Fig. 2

Linear range of observation of the LnTL, TC, and TG, with age. a LnTL (the natural logarithm of telomere length), b TC (total cholesterol), and c TG (triglycerides) with age. LnTL r = −0.750, p = 0.052; TC r = 0.893, p = 0.007; TG r = 0.643, p = 0.119

Because ALB had a good correlation and the LnTL reflected the survival advantage on a molecular level, both were used to develop our model. Using the Z values of ALB as the x-axis, and LnTL as the y-axis, the I quadrant represented the Z value of both LnTL and ALB (>0); the II quadrant represented the Z value of LnTL (>0) and the Z value of ALB (<0); the III quadrant represented the Z value of both LnTL and ALB (<0); and the IV quadrant represented the Z value of LnTL (<0) and the Z value of ALB (>0). Analyses of the young age group (n = 40; age 20–39 years), the middle-aged group (n = 30; age 40–59 years), and the older-aged group (n = 30; age 60–90 years) in the four quadrants of the distribution and the percentages, are shown in Fig. 3.
Fig. 3

Distributions of a the young group, b the middle-aged group, and c the older age group in the two-dimensional model. The x-axis shows the Z value of albumin (ALB) and the y-axis shows the value of LnTL (the natural logarithm of telomere length). There was significant difference between the constituent ratios of each group (p = 0.004)

There was no significant difference in the distribution of the four quadrants in the diabetic patient group and the control group (p = 0.413) (Table 2). However, there were significant differences in the constituent ratio of each age group (p = 0.004), as shown in Fig. 3.

The Zs was calculated as follows:
$$ {\text{Z}}_{\text{s}} = [{\text{Z}}\;({\text{LnTL}}) + {\text{Z}}({\text{ALB}})]/2, $$
so when Zs is larger than 1.64, we set a 95% reference interval (single tail). The analyses of the differences of Zs in the diabetic group and control group are shown in Table 3, and were significant (p = 0.026).
Table 2

Distribution of diabetes and control subjects in the four quadrants

Group

Age (\( {\bar{\text{x}}} \))

I (%)

II (%)

III (%)

IV (%)

χ 2

p

Diabetes

65.19

25.0

10.0

27.5

37.5

2.862

0.413

Control

63.12

35

16.7

18.3

30.0

I represents the Z value of LnTL and ALB both >0; II represents the Z value of LnTL >0 and the Z value of ALB <0; III represents the Z value of LnTL <0 and the Z value of ALB <0; and IV represents the Z value of LnTL <0, and the Z value of ALB >0. All abbreviations are the same as in Table 1

Table 3

Comparisons of the percentage between the diabetes and control groups using cutoff Zs values (1.64)

Group

Age (\( {\bar{\text{x}}} \))

Zs ≤ 1.64 (%)

Zs > 1.64 (%)

χ 2

p

Diabetes

65.19

90.5

9.5

5.948

0.026

Control

63.12

100.0

0.0

The 95% confidence interval was Z > 1.64 (single-tail)

Discussion

In this study, the preliminary screening included ALB, TC, and TG from nine parameters due to three parameters representing relationships with aging. ALB showed a good linear relationship with age, indicating an aging indicator. We found that the TC and TG had a reverse turning point in the elderly group [28], indicating that the two indicators showed survival advantage indicators similar to telomere length. However, the inflection point was obviously greater for telomere length compared with the above two parameters. Therefore, the final parameter of the survival advantage model was the relative length of the telomere.

For elderly people, longer telomeres may be selective for relatively healthy people, or the elderly having shorter telomeres may have died, and therefore it was not possible to obtain a sample. Likewise, the healthy elderly with a stronger survival and longer telomere length could reflect an organismic survival advantage [1, 9, 14]. It is necessary to establish a new system to evaluate the survival advantages of peers. The Z value of LnTL was relatively smaller than ALB indicating a survival advantage. The two parameters of ALB and LnTL changed independently. Therefore, after standardization, these two parameters were used to establish the two-dimensional evaluation system.

Z value was used to standardize the different parameters. For comparable Z values of ALB and LnTL, we used the standardization to establish a two-dimensional system, when the Z value of LnTL was smaller than ALB (IV quadrant); indicating a survival advantage. Theoretically, the score was equivalent to zero, but individuals with different Z values may not reach the theoretical value. The I quadrant indicated that some individuals were biologically aging and therefore had a poorer survival advantage; the II quadrant indicated that some individuals were not biologically aging and had a poorer survival advantage; the III quadrant indicated that some individuals were not biologically aging and therefore had a stronger survival advantage; and, the IV quadrant indicated that some individuals were biologically aging and had a stronger survival advantage compared to the peers. Therefore, the distribution ratio of individuals among each group in the four quadrants could predict the characteristics of aging.

Our results showed that the II and the IV quadrants represented individuals with poorer and stronger survive advantages compared to the peers, respectively. The younger group and older group mainly distributed in quadrants III and I, respectively, and they were not evenly distributed in the four quadrants, while the middle-aged group was almost evenly distributed in the four quadrants. This demonstrated that the system was effective.

Although our two-dimensional analysis showed no significant difference between the diabetic group and the control group, a greater degree of aging was found in diabetes patients using the comprehensive analysis. Perhaps the chronic diseases did not cause severe enough damage to cause mortality at the molecular level [29]. This finding could also be a characteristic of diabetes. In the future, other diseases such as cancer or heart disease should be studied using the two-dimensional system.

Conclusion

Our two-dimensional model system using ALB and LnTL was valid and may have potential applications in the evaluation of aging status at the molecular level for the observation of disease characteristics.

Abbreviations

LnTL: 

the natural logarithm of telomere length

ALB: 

albumin

TP: 

total proteins

TG: 

triglycerides

TC: 

total cholesterol

ALT: 

alanine amino transferase

AST: 

aspartate amino transferase

ALP: 

alkaline phosphatase

GGT: 

gamma glutamyl transferase

LDH: 

lactate dehydrogenase

Declarations

Authors’ contributions

YZ and HL were participated in the design of the study, performed the statistical analysis and YZ wrote the paper. YZ and SL were performed the data acquisition and experiments. All authors read and approved the final manuscript.

Acknowledgements

We thank Keke Fan, Jianan Zhao, Xinyan Feng, Congcong Shang, for their help with data acquisition.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The Institutional Ethics Committee of Dalian Medical University approved the study and waived the need for written informed consent from the participants due to the observational nature of the study.

Funding

This research did not receive any specific grant funding from agencies in the public, commercial, or not-for-profit sectors.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
College of Medical Laboratory, Dalian Medical University

References

  1. Chongliang F, Yuzhong L, Qian S, Xiliang L, Hui L. Development of a prognostic score using the complete blood cell count for survival prediction in unselected critically ill patients. Biomed Res Int. 2013;2013:105319.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Liu W, Wang W, Tian G, Xie W, Lei L, Liu J, Huang W, Xu L, Li E. Topologically inferring pathway activity for precise survival outcome prediction: breast cancer as a case. Mol Bio Syst. 2017;13(3):537–48.Google Scholar
  3. Meissner C, Ritz-Timme S. Molecular pathology and age estimation. Forensic Sci Int. 2010;203(1–3):34–43.View ArticlePubMedGoogle Scholar
  4. Heidinger BJ, Blount JD, Boner W, Griffiths K, Metcalfe NB, Monaghan P. Telomere length in early life predicts lifespan. Proc Natl Acad Sci USA. 2012;109(5):1743–8.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Bernardes de Jesus B, Blasco MA. Assessing cell and organ senescence biomarkers. Circ Res. 2012;111(1):97–109.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Bailey AJ. Molecular mechanisms of ageing in connective tissues. Mech Ageing Dev. 2001;122(7):735–55.View ArticlePubMedGoogle Scholar
  7. Ryazanov AG, Nefsky BS. Protein turnover plays a key role in aging. Mech Ageing Dev. 2002;123(2–3):207–13.View ArticlePubMedGoogle Scholar
  8. Zubakov D, Liu F, Kokmeijer I, Choi Y, van Meurs JB, van IJcken WF, Uitterlinden AG, Hofman A, Broer L, van Duijn CM, Lewin J, Kayser M. Human age estimation from blood using mRNA, DNA methylation, DNA rearrangement, and telomere length. Forensic Sci Int Genet. 2016;24:33–43.View ArticlePubMedGoogle Scholar
  9. Bernadotte A, Mikhelson VM, Spivak IM. Markers of cellular senescence. Telomere shortening as a marker of cellular senescence. Aging. 2016;8(1):3–11.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Zvereva MI, Shcherbakova DM, Dontsova OA. Telomerase: structure, functions, and activity regulation. Biochemistry. 2010;75(13):1563–83.PubMedGoogle Scholar
  11. Dong Y, Zhang G, Yuan X, Zhang Y, Hu M. Telomere length and telomere repeating factors: cellular markers for post-traumatic stress disorder-like model. J Affect Disord. 2016;195:156–62.View ArticlePubMedGoogle Scholar
  12. Ye J, Renault VM, Jamet K, Gilson E. Transcriptional outcome of telomere signalling. Nat Rev Genet. 2014;15(7):491–503.View ArticlePubMedGoogle Scholar
  13. Holohan B, De Meyer T, Batten K, Mangino M, Hunt SC, Bekaert S, De Buyzere ML, Rietzschel ER, Spector TD, Wright WE, Shay JW. Decreasing initial telomere length in humans intergenerationally understates age-associated telomere shortening. Aging Cell. 2015;14(4):669–77.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Lapham K, Kvale MN, Lin J, Connell S, Croen LA, Dispensa BP, Fang L, Hesselson S, Hoffmann TJ, Iribarren C, Jorgenson E, Kushi LH, Ludwig D, Matsuguchi T, McGuire WB, Miles S, Quesenberry CP Jr, Rowell S, Sadler M, Sakoda LC, Smethurst D, Somkin CP, Van Den Eeden SK, Walter L, Whitmer RA, Kwok PY, Risch N, Schaefer C, Blackburn EH. Automated assay of telomere length measurement and informatics for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort. Genetics. 2015;200(4):1061–72.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.View ArticlePubMedGoogle Scholar
  16. Sutin AR, Terracciano A, Deiana B, Uda M, Schlessinger D, Lakatta EG, Costa PT Jr. Cholesterol, triglycerides, and the Five-Factor Model of personality. Biol Psycho. 2010;84(2):186–91.View ArticleGoogle Scholar
  17. Luna C, Alique M, Navalmoral E, Noci MV, Bohorquez-Magro L, Carracedo J, Ramírez R. Aging-associated oxidized albumin promotes cellular senescence and endothelial damage. Clin Interv Aging. 2016;11:225–36.PubMedPubMed CentralGoogle Scholar
  18. Chhavi N, Zutshi K, Singh NK, Awasthi A, Goel A. Serum liver enzyme pattern in birth asphyxia associated liver injury. Pediatr Gastroenterol Hepatol Nutr. 2014;17(3):162–9.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Schmucker DL. Aging and the liver: an update. J Gerontol A Biol Sci Med Sci. 1998;53(5):B315–20.View ArticlePubMedGoogle Scholar
  20. Yin D, Chen K. The essential mechanisms of aging: irreparable damage accumulation of biochemical side-reactions. Exp Gerontol. 2005;40(6):455–65.View ArticlePubMedGoogle Scholar
  21. Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer’s disease. Neurosci Lett. 2006;408(1):68–72.View ArticlePubMedGoogle Scholar
  22. Liu Z, Zhong G, Li S, Deng W, Zhang Y, Qian D, Jin L, Wang X. Use of serum albumin and activities of daily living to predict mortality in long-lived individuals over 95 years of age: a population-based study. Age (Dordr). 2015;37(4):9809.View ArticlePubMedGoogle Scholar
  23. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14(2):185–92.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34(6):1329–36.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Hui L, Shijun L, Xinyu Z, Yuai W, Xiaoting X. Objective assessment of stress levels and health status using routinely measured clinical laboratory parameters as biomarkers. Biomarkers. 2011;16(6):525–9.View ArticlePubMedGoogle Scholar
  27. Hongwei W, Xinyu Z, Guihong L, Xiliang L, Hui L. Nonspecific biochemical changes under different health statuses and a quantitative model based on biological markers to evaluate systemic function in humans. Clin Lab. 2010;56(5–6):223–5.PubMedGoogle Scholar
  28. Takata Y, Ansai T, Soh I, Awano S, Nakamichi I, Akifusa S, Goto K, Yoshida A, Fujii H, Fujisawa R, Sonoki K. Serum total cholesterol concentration and 10-year mortality in an 85-year-old population. Clin Interv Aging. 2014;9:293–300.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Hui L. Aging and chronic disease as independent causative factors for death and a programmed onset for chronic disease. Arch Gerontol Geriatr. 2015;60(1):178–82.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2017